Michael J. Sofia

5.4k total citations · 1 hit paper
122 papers, 3.8k citations indexed

About

Michael J. Sofia is a scholar working on Molecular Biology, Hepatology and Epidemiology. According to data from OpenAlex, Michael J. Sofia has authored 122 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Molecular Biology, 44 papers in Hepatology and 40 papers in Epidemiology. Recurrent topics in Michael J. Sofia's work include Hepatitis C virus research (44 papers), Hepatitis B Virus Studies (36 papers) and HIV/AIDS drug development and treatment (27 papers). Michael J. Sofia is often cited by papers focused on Hepatitis C virus research (44 papers), Hepatitis B Virus Studies (36 papers) and HIV/AIDS drug development and treatment (27 papers). Michael J. Sofia collaborates with scholars based in United States, United Kingdom and China. Michael J. Sofia's co-authors include Phillip A. Furman, Bruce S. Ross, Wonsuk Chang, Angela M. Lam, Michaël Otto, Ralph T. Mosley, Congrong Niu, Shalini Bansal, Holly M. Micolochick Steuer and Christine Espiritu and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Michael J. Sofia

121 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

2010 486 citations Michael J. Sofia, Donghui Bao et al. Journal of Medicinal Chemistry profile →

Peers

Countries citing papers authored by Michael J. Sofia

Since Specialization

Citations

This map shows the geographic impact of Michael J. Sofia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Sofia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Sofia more than expected).

Fields of papers citing papers by Michael J. Sofia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Sofia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Sofia. The network helps show where Michael J. Sofia may publish in the future.

Co-authorship network of co-authors of Michael J. Sofia

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Sofia. A scholar is included among the top collaborators of Michael J. Sofia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Sofia. Michael J. Sofia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of a Scalable Manufacturing Process for AB-343 Drug Substance: A Potential Candidate for the Treatment of Coronavirus Infections 2025 ·Organic Process Research & Development ·Jeremy D. Mason, (unknown), (unknown), Zhenhua Wu, Rajeev Kumar Singh, (unknown), Jia Liu, (unknown), Xu Wang, Michael J. Sofia, (unknown)	0
2	Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly Modulators 2024 ·ACS Medicinal Chemistry Letters ·Eugen F. Mesaros, Andrew G. Cole, Steven G. Kultgen, Nagraj Mani, Kristi Fan, (unknown), (unknown), (unknown), Holly M. Micolochick Steuer, (unknown), (unknown), Troy O. Harasym, Angela M. Lam, Emily P. Thi, Bruce D. Dorsey, Michael J. Sofia	2
3	Rational Design, Synthesis, and Structure–Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836 2024 ·Journal of Medicinal Chemistry ·Andrew G. Cole, Steven G. Kultgen, Nagraj Mani, Kristi Fan, (unknown), (unknown), Bruce D. Dorsey, Eugen F. Mesaros, Emily P. Thi, (unknown), (unknown), Troy O. Harasym, Amy C. H. Lee, Andrea Olland, R.K. Suto, Michael J. Sofia	4
4	Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161 2024 ·Viruses ·Angela M. Lam, (unknown), Muhammad Sheraz, Fei Liu, Emily P. Thi, (unknown), Andrea Cuconati, Holly M. Micolochick Steuer, (unknown), (unknown), Jeremy D. Mason, (unknown), Andrew G. Cole, Troy O. Harasym, Michael J. Sofia	5
5	Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B 2022 ·Hepatology Communications ·Man‐Fung Yuen, Elina Berliba, Wattana Sukeepaisarnjaroen, Sang Hoon Ahn, Tawesak Tanwandee, Young‐Suk Lim, Yoon Jun Kim, Kittiyod Poovorawan, Pisit Tangkijvanich, Christian Schwabe, Timothy Eley, J. B. Brown, Amy C. H. Lee, Emily P. Thi, Bhavna Paratala, Nagraj Mani, Michael J. Sofia, Gastón Picchio, Karen Sims, Edward Gane	17
6	Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients 2020 ·Scientific Reports ·Jin Hyang Kim, Alip Ghosh, Natarajan Ayithan, Sara Romani, Arshi Khanam, Jang‐June Park, René Rijnbrand, Lydia Tang, Michael J. Sofia, Shyam Kottilil, Chris B. Moore, Bhawna Poonia	56
7	Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors 2019 ·Antiviral Research ·(unknown), Nagraj Mani, Bruce D. Dorsey, (unknown), René Rijnbrand, Michael J. Sofia, John E. Tavis	30
8	Enter Sofosbuvir: The Path to Curing HCV 2016 ·Cell ·Michael J. Sofia	7
9	Structural basis for RNA replication by the hepatitis C virus polymerase 2015 ·Science ·T.C. Appleby, Jason K. Perry, Eisuke Murakami, Ona Barauskas, Joy Y. Feng, Aesop Cho, David Fox, Diana Wetmore, Mary E. McGrath, Adrian S. Ray, Michael J. Sofia, S. Swaminathan, Thomas E. Edwards	254
10	β-d-2′-α-F-2′-β-C-Methyl-6-O-substituted 3′,5′-cyclic phosphate nucleotide prodrugs as inhibitors of hepatitis C virus replication: A structure–activity relationship study 2012 ·Bioorganic & Medicinal Chemistry Letters ·Jinfa Du, Donghui Bao, (unknown), Ying Jiang, P. Ganapati Reddy, Hai‐Ren Zhang, Bruce S. Ross, Shalini Bansal, Haiying Bao, Christine Espiritu, Angela M. Lam, Eisuke Murakami, Congrong Niu, Holly M. Micolochick Steuer, Phillip A. Furman, Michaël Otto, Michael J. Sofia	13
11	Discovery and optimization of (R)-prolinol-derived agonists of the Growth Hormone Secretagogue receptor (GHSR) 2008 ·Bioorganic & Medicinal Chemistry Letters ·Weixu Zhai, Neil Flynn, Daniel Angelo Longhi, Joseph A. Tino, Brian J. Murphy, (unknown), David A. Gordon, (unknown), Shuhao Shi, Robert H. Stoffel, Bao‐Qing Ma, Michael J. Sofia, Samuel W. Gerritz	5
12	3-Azido-3-deoxy-glycopyranoside derivatives as scaffolds for the synthesis of carbohydrate-Based universal pharmacophore mapping libraries 2003 ·Bioorganic & Medicinal Chemistry Letters ·Rakesh K. Jain, (unknown), Chunguang Wang, (unknown), Hui‐Ming Wang, (unknown), (unknown), David Gange, Michael J. Sofia	16
13	Pharmacologic actions of the second generation leukotriene B 4 receptor antagonist LY293111: in vivo pulmonary studies 2000 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Steven A. Silbaugh, Peter W. Stengel, Sandra L. Cockerham, Larry L. Froelich, A.M. Bendele, Stephen M. Spaethe, Michael J. Sofia, J. Scott Sawyer, William T. Jackson	14
14	Carbohydrate-based combinatorial libraries 1997 ·Molecular Diversity ·Michael J. Sofia	39
15	The Discovery of LY293111, a Novel, Potent and Orally Active Leukotriene B4 Receptor Antagonist of the Biphenylphenol Class 1997 ·Advances in experimental medicine and biology ·Michael J. Sofia, Paul E. Floreancig, (unknown), Stephen Baker, (unknown), J. Scott Sawyer, (unknown), Sandra L. Cockerham, J H Fleisch, Larry L. Froelich, William T. Jackson, Philip Marder, (unknown), D L Saussy, Steven A. Silbaugh, Stephen M. Spaethe, Peter W. Stengel	7
16	Aerosolized LTB4 produces delayed onset increases in pulmonary gas trapping 1996 ·Prostaglandins Leukotrienes and Essential Fatty Acids ·Steven A. Silbaugh, Peter W. Stengel, Sandra L. Cockerham, Larry L. Froelich, A.M. Bendele, Marian K. Rippy, Stephen Baker, Michael J. Sofia, William T. Jackson	1
17	o-Phenylphenols: potent and orally active leukotriene B4 receptor antagonists 1993 ·Journal of Medicinal Chemistry ·Michael J. Sofia, Paul E. Floreancig, Nicholas J. Bach, Stephen Baker, Sandra L. Cockerham, Jerome H. Fleisch, Larry L. Froelich, William T. Jackson, Philip Marder	8
18	Flow cytometric evaluation of the effects of leukotriene B4 receptor antagonists (LY255283 and SC-41930) on calcium mobilization and integrin expression of activated human neutrophils 1992 ·Prostaglandins Leukotrienes and Essential Fatty Acids ·Philip Marder, Richard M. Schultz, Stephen M. Spaethe, Michael J. Sofia, David K. Herron	16
19	Pulmonary responses of the guinea pig to inhaled A23187: A brief review 1992 ·Inflammation Research ·Steven A. Silbaugh, Michael J. Sofia, Robert L. Hamill, Peter W. Stengel	1
20	The first potent inhibitor of squalene synthase: a profound contribution of an ether oxygen to inhibitor-enzyme interaction 1991 ·Journal of the American Chemical Society ·Scott A. Biller, Michael J. Sofia, (unknown), Cornelia J. Forster, Eric M. Gordon, Thomas Harrity, (unknown), Carl P. Ciosek	62

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact